RESEARCH PAPER
Late presentation: a stumbling block to HIV viral suppression in a low income country
 
More details
Hide details
1
Tumbi Regional Referral Hospital, Kibaha, Tanzania
 
2
TMJ Hospital, Mikocheni, Dar es Salaam, Tanzania
 
 
Submission date: 2020-10-26
 
 
Final revision date: 2021-10-02
 
 
Acceptance date: 2021-10-03
 
 
Publication date: 2022-04-26
 
 
HIV & AIDS Review 2022;21(2):115-120
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Tenofovir-based regimens have been recently introduced as first-line antiretroviral treatment (ART) to human immunodeficiency virus (HIV) patients in Tanzania. Limited information on HIV viral suppression and its’ associated factors exists in Tanzania since the adoption of this intervention at a public health level. The aim of the present study was to determine HIV viral suppression rate and assess its’ associated factors among patients attending Temeke Regional Referral Hospital care and treatment clinic after twelve months of using antiretroviral therapy.

Material and methods:
Hospital-based cross-sectional study was performed to assess factors associated with HIV viral suppression. Viral load suppression was defined as HIV-RNA below 50 copies/ml, and late presentation was defined in a person who presented to care and treatment facility with WHO HIV clinical stage III or IV and/or baseline CD4+ T lymphocyte count of less than 350 cells/µl.

Results:
Among the 188 participants who were interviewed, a total of 149 (79.3%) achieved viral suppression after one year of using ART. Late presentation to health facility (OR = 3.4; 95% CI: 1.6-7.4; p < 0.01) was independently associated with inability to achieve viral suppression at 12 months.

Conclusions:
HIV testing services should be strengthened in order to achieve the UNAIDS 90-90-90 target through early detection of HIV disease.

 
REFERENCES (18)
1.
UNAIDS 2018. Global HIV and AIDS statistics – 2018 fact sheet. [Internet]. Available at: https://scholar.google.com/sch...=.
 
2.
Avert.org. 2020. Tanzania 90-90-90 progress. Available at: https://www.avert.org/printpdf... (Accessed: 02.05.2020).
 
3.
LeMessurier J, Traversy G, Varsaneux O, et al. Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review. CMAJ 2018; 190: E1350-E1360.
 
4.
Mugusi F, Mugusi S, Bakari M, et al. Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries; the Tanzanian experience. Trop Med Int Health 2009; 14: 1226-1232.
 
5.
d’Amour Ndahimana J, Riedel DJ, Mwumvaneza M, et al. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Trop Med Int Health 2016; 21: 928-935.
 
6.
Mosha F, Sangeda RZ, Ocheng D, et al. Factors influencing adherence to antiretroviral therapy among people living with HIV in an urban and rural setting, Tanzania. East Cent African J Pharm Sci 2002; 22: 3-12.
 
7.
Barth RE, van der Loeff MFS, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programs in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10: 155-166.
 
8.
Rangarajan S, Donn JC, Giang LT, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J Virus Erad 2016; 2: 94-101.
 
9.
Ntamatungiro AJ, Muri L, Glass TR, et al. Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. J Anti­microb Chemother 2017; 72: 2069-2074.
 
10.
Johannessen A, Naman E, Kivuyo SL, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 2009; 9: 108.
 
11.
Hawkins C, Ulenga N, Liu E, et al. HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults. J Antimicrob Chemother 2016; 71: 1966-1974.
 
12.
Girardi E, Sabin CA. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46 (Suppl 1): S3-8.
 
13.
Samet JH, Retondo MJ, Freedberg KA, Stein MD, Heeren T, Libman H. Factors associated with initiation of primary. Am J Med 1994; 97: 347-353.
 
14.
Kigozi IM, Dobkin LM, Martin JN, et al. Late disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic Syndr 2009; 52: 280-289.
 
15.
Mosha F, Muchunguzi V, Matee M, et al. Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. BMC Public Health 2013; 13: 38-38.
 
16.
Kalichman SC, Grebler T, Amaral CM, et al. Viral suppression and antiretroviral medication adherence among alcohol using HIV positive adults. Int J Behav Med 2015; 21: 811-820. Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR. An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis 2011; 53: 952-960.
 
17.
Sangeda RZ, Mosha F, Aboud S, et al. Predictors of non-adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania. Drug Healthc Patient Saf 2018; 10: 79-88.
 
18.
Ugbena R, Aberle-Grasse J, Diallo K, et al. Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria. Clin Infect Dis 2012; 54 (Suppl 4): 375-380.
 
eISSN:1732-2707
ISSN:1730-1270
Journals System - logo
Scroll to top